Several studies including ours have also demonstrated that BCG could be engineered to express mucin-1 (MUC1), a candidade tumor-associated antigen for breast cancer and other epithelial adenocarcinomas, in a manner of multiple tandem repeats with coexpression of IL-2, GM-CSF, or CD80 [95–99]. The gene discussed is MUC1; the disease is neoplasm.